BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Oct 18, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Vivitrol naltrexone regulatory update

FDA approved an sNDA from Alkermes to extend the label for Vivitrol naltrexone to prevent relapse to opioid use in opioid-dependent patients following opioid...

Read the full 97 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >